The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

Recently revealed trial results for Roche's experimental weight-management drug suggest Viking Therapeutics is on the right ...

Roche said on Wednesday the promising results of an early-stage trial of its experimental weight-loss pill that bolstered its ...

Shares in Roche fell on Thursday after an early-stage obesity pill candidate that carries high market hopes was linked to a ...

Roche's experimental weight-loss pill, CT-996, showed promising early-stage trial results, causing shares to rise. However, ...

Roche presented early-stage data on its obesity injection and pill at EASD. Meanwhile, Oura enters into metabolic health ...

Roche’s stock fell after new data from an early-stage clinical trial of its closely watched oral weight-loss drug candidate ...

Roche's diversified portfolio and ongoing GLP-1 developments offer decent upside with limited downside. Read more about RHHBY ...

For the second trading session in less than a week, Roche Holding ( RHHBY -6.02%) stock really took it on the chin Wednesday.

Roche RHHBY presented results of an early-stage study on its experimental obesity drug, CT-996, at the European Association for the Study of Diabetes annual meeting. CT-996 is an investigational, once ...

When doses werer increased rapidly in a Phase I study, patients on Roche’s investigational oral GLP-1 receptor agonist experienced nausea, vomiting, constipation, diarrhea, as well as abdominal and ...